BACKGROUND: To study the effects of deferring pegfilgrastim until day 4 on the reduction of chemotherapy-induced leukocytopenia. PATIENTS AND METHODS: Patients of age 61-80 years with aggressive lymphoma were randomly assigned to receive 6 mg pegfilgrastim on day 2 or 4 of a 2-week chemotherapy regimen (R-CHOP-14). RESULTS:Two hundred and ninety-two and 313 chemotherapy cycles were evaluable in 103 patients. Post-nadir pegfilgrastim serum levels were higher after day 4 than after day 2 application. This was associated with an attenuated leukocyte nadir after day 4 pegfilgrastim and there were fewer days with leukocytes <2 × 10(3)/mm(3) compared with day 2 pegfilgrastim. Grade 3 and 4 leukocytopenias (70% versus 43.3%; P < 0.001) and grade 4-only leukocytopenias (47% versus 20.5%; P < 0.001) were more frequent after day 2 pegfilgrastim. There were more chemotherapy cycles with grade 3 and 4 infections after day 2 than day 4 pegfilgrastim (9.4% versus 6.0%; P = 0.118). Interventional antibiotics were given more often after day 2 than after day 4 pegfilgrastim (30.7% versus 21.9% of cycles; P = 0.008). There were five deaths during leukocytopenia after day 2 and none after day 4 pegfilgrastim (P = 0.027). CONCLUSIONS: Administration of pegfilgrastim on day 4 was more effective in reducing severe leukocytopenias and resulted in fewer deaths during leukocytopenia. Pegfilgrastim should be given on day 4 to better exploit its myeloprotective potential.
RCT Entities:
BACKGROUND: To study the effects of deferring pegfilgrastim until day 4 on the reduction of chemotherapy-induced leukocytopenia. PATIENTS AND METHODS: Patients of age 61-80 years with aggressive lymphoma were randomly assigned to receive 6 mg pegfilgrastim on day 2 or 4 of a 2-week chemotherapy regimen (R-CHOP-14). RESULTS: Two hundred and ninety-two and 313 chemotherapy cycles were evaluable in 103 patients. Post-nadir pegfilgrastim serum levels were higher after day 4 than after day 2 application. This was associated with an attenuated leukocyte nadir after day 4 pegfilgrastim and there were fewer days with leukocytes <2 × 10(3)/mm(3) compared with day 2 pegfilgrastim. Grade 3 and 4 leukocytopenias (70% versus 43.3%; P < 0.001) and grade 4-only leukocytopenias (47% versus 20.5%; P < 0.001) were more frequent after day 2 pegfilgrastim. There were more chemotherapy cycles with grade 3 and 4 infections after day 2 than day 4 pegfilgrastim (9.4% versus 6.0%; P = 0.118). Interventional antibiotics were given more often after day 2 than after day 4 pegfilgrastim (30.7% versus 21.9% of cycles; P = 0.008). There were five deaths during leukocytopenia after day 2 and none after day 4 pegfilgrastim (P = 0.027). CONCLUSIONS: Administration of pegfilgrastim on day 4 was more effective in reducing severe leukocytopenias and resulted in fewer deaths during leukocytopenia. Pegfilgrastim should be given on day 4 to better exploit its myeloprotective potential.
Authors: Mehmet Asim Bilen; Diana H Cauley; Bradley J Atkinson; Hsiang-Chun Chen; Diana H Kaya; Xuemei Wang; Raghu Vikram; Shi-Ming Tu; Paul G Corn; Jeri Kim Journal: Clin Genitourin Cancer Date: 2016-12-13 Impact factor: 2.872
Authors: Matteo Lambertini; Paolo Bruzzi; Francesca Poggio; Simona Pastorino; Giovanni Gardin; Matteo Clavarezza; Claudia Bighin; Paolo Pronzato; Lucia Del Mastro Journal: Support Care Cancer Date: 2015-08-27 Impact factor: 3.603
Authors: Sol Cortés de Miguel; Miguel Ángel Calleja-Hernández; Salomón Menjón-Beltrán; Inmaculada Vallejo-Rodríguez Journal: Support Care Cancer Date: 2014-10-07 Impact factor: 3.603
Authors: O Vainas; S Ariad; O Amir; W Mermershtain; V Vainstein; M Kleiman; O Inbar; R Ben-Av; A Mukherjee; S Chan; Z Agur Journal: Br J Cancer Date: 2012-07-19 Impact factor: 7.640
Authors: Karin Hohloch; Carsten Zwick; Marita Ziepert; Dirk Hasenclever; Ulrich Kaiser; Andreas Engert; Heinz-Gert Höffkes; Frank Kroschinsky; Rolf Mesters; Andreas C Feller; Markus Löffler; Lorenz Trümper; Michael Pfreundschuh Journal: Springerplus Date: 2014-01-03
Authors: Markus Scholz; Sibylle Schirm; Marcus Wetzler; Christoph Engel; Markus Loeffler Journal: Theor Biol Med Model Date: 2012-07-30 Impact factor: 2.432